(ARE) Alexandria Real Estate Equities Now Expects 2026 Adjusted FFO Range $6.38-$6.42, vs. FactSet Est of $6.39

Alexandria Real Estate Equities (ARE) updated its 2026 adjusted FFO guidance to $6.38-$6.42, slightly below FactSet's estimate of $6.39. The company also reported declines in Q3 adjusted FFO and revenue.

Original reporting
Published Oct 26, 2026, 8:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 9:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ARE
Neutral
high confidence
Mentioned
$ARE
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$ARENeutralMed
01

Why it matters

The new FFO guidance provides the first forward‑looking metric for 2026, offering traders a fresh data point to reassess valuation.

02

Market read

Guidance aligns closely with consensus, suggesting limited but actionable price movement.

03

What to watch

Potential upside from upcoming lease renewals or cost‑saving initiatives not reflected in the guidance.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Alexandria Real Estate Equities (ARE) is a leading office REIT focused on life‑science and technology campuses.

Company-level read

Ticker impact

$ARENeutralHigh confidence
Context

Alexandria Real Estate Equities released its 2026 adjusted FFO guidance range of $6.38‑$6.42, a new primary disclosure.

Expected impact

slight downside pressure as investors price in the lower bound of the guidance range

Evidence & confidence

The guidance range brackets the consensus estimate, so the market may view the low end as a miss, prompting modest selling.

Market effects

The REIT sector may see slight pressure as peers' valuations are tied to FFO guidance.

U.S. real‑estate market sentiment could be modestly affected.

Limited; primarily impacts U.S. REIT investors.

Counterpoint

If the market overreacts to the low end, the stock could rebound on the high end of the range.

Key entities

  • Alexandria Real Estate Equities

    U.S. listed REIT (ticker ARE) providing office space for biotech and tech firms.

Related articles

$AREHigh

BofA downgrades Alexandria Real Estate stock rating on earnings concerns

BofA Securities downgraded Alexandria Real Estate Equities (NYSE:ARE) to Underperform, lowering its price target to $45 from $55. The company reported a $8.40 per share loss and 9.77% revenue decline over the last year, despite a 6.5% dividend yield. BofA cited declining earnings and leasing challenges as reasons for the downgrade. Alexandria's Q3 2026 results showed mixed performance, with revenue exceeding estimates but significant earnings loss due to real estate impairments.

$AREMedAI 8/10

Alexandria Real Estate Equities Inc (ARE) (Q3 2026) Earnings Call Highlights: Record

Alexandria Real Estate Equities Inc (ARE) reported Q3 2026 earnings with record leasing of 1.2M sq ft, strong liquidity at $4.6B, and $1.7B in capital raised. However, same-property NOI declined 6.7% (GAAP) due to lower occupancy (87.1%). The company expects temporary occupancy pressure in early 2027 and recognized $638M in impairments. Management discussed development spending, tenant wind-downs, and disposition strategies during the earnings call.

$AREHighAI 8/10

KKR Makes $475M Bet in San Diego's Life Science Market

KKR invested $475M in Alexandria Real Estate Equities' 2M sq ft San Diego life science campus, taking a 49% stake. The joint venture will support leasing and development. Alexandria's CEO called it a step to optimize capital. Tenants include Bristol Myers Squibb and Eli Lilly. KKR has invested $20B in life sciences since 2004.

$AREHighAI 8/10

KKR Acquires 49% Stake in Alexandria Real Estate Equities' Campu

KKR & Co. acquired a 49% stake in Alexandria Real Estate Equities Inc.'s (ARE) Campus Point life science Megacampus for $475 million. ARE retains majority ownership and management control. The company's P/S ratio is 2.35, below its historical median, and it has a GF Score of 61/100, indicating moderate fundamental health with weaknesses in financial strength and valuation.

$AREMedAI 8/10

KKR invests $475m in Alexandria Real Estate Equities’ Campus Point

KKR invested $475m in Alexandria Real Estate Equities' Campus Point, a 2M sq. ft. life sciences campus in San Diego. KKR holds a 49% stake, while Alexandria retains majority ownership. The deal provides Alexandria with capital for development and leasing. Campus Point is home to companies like Novartis.